Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

[SARS vaccines].

Identifieur interne : 002F63 ( Main/Exploration ); précédent : 002F62; suivant : 002F64

[SARS vaccines].

Auteurs : Fumihiro Taguchi

Source :

RBID : pubmed:18939499

Descripteurs français

English descriptors

Abstract

Severe acute respiratory syndrome (SARS) is an emerging disease derived from wild animals and is highly pathogenic with a high mortality. A novel coronavirus SARS coronavirus was identified to be a causative agent for SARS. Since its discovery, many trials have been executed to establish the prophylactic and therapeutics toward SARS using laboratory animals. A number of different types of vaccines, such as inactivated virus vaccine, subunit vaccine, DNA vaccine and vaccine using viral expression vector as well as attenuated live vaccine so far reported indicate that neutralizing antibodies play an important role for protection. However, vaccine applicable to humans with the high efficacy and safety has not yet been reported.

PubMed: 18939499


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">[SARS vaccines].</title>
<author>
<name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
<affiliation>
<nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases.</nlm:affiliation>
<wicri:noCountry code="subField">National Institute of Infectious Diseases</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18939499</idno>
<idno type="pmid">18939499</idno>
<idno type="wicri:Area/PubMed/Corpus">001A47</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A47</idno>
<idno type="wicri:Area/PubMed/Curation">001A47</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A47</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001961</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001961</idno>
<idno type="wicri:Area/Ncbi/Merge">001D70</idno>
<idno type="wicri:Area/Ncbi/Curation">001D70</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001D70</idno>
<idno type="wicri:Area/Main/Merge">003027</idno>
<idno type="wicri:Area/Main/Curation">002F63</idno>
<idno type="wicri:Area/Main/Exploration">002F63</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">[SARS vaccines].</title>
<author>
<name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
<affiliation>
<nlm:affiliation>Department of Virology III, National Institute of Infectious Diseases.</nlm:affiliation>
<wicri:noCountry code="subField">National Institute of Infectious Diseases</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Nihon rinsho. Japanese journal of clinical medicine</title>
<idno type="ISSN">0047-1852</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Drug Design</term>
<term>Genetic Vectors</term>
<term>Humans</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Severe Acute Respiratory Syndrome (virology)</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, DNA</term>
<term>Vaccines, Subunit</term>
<term>Viral Proteins</term>
<term>Viral Vaccines (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Protéines virales</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (virologie)</term>
<term>Vaccins antiviraux (effets indésirables)</term>
<term>Vaccins atténués</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins à ADN</term>
<term>Vecteurs génétiques</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en">
<term>Vaccines, Attenuated</term>
<term>Vaccines, DNA</term>
<term>Vaccines, Subunit</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Vaccins antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Drug Design</term>
<term>Genetic Vectors</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Protéines virales</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins atténués</term>
<term>Vaccins sous-unitaires</term>
<term>Vaccins à ADN</term>
<term>Vecteurs génétiques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is an emerging disease derived from wild animals and is highly pathogenic with a high mortality. A novel coronavirus SARS coronavirus was identified to be a causative agent for SARS. Since its discovery, many trials have been executed to establish the prophylactic and therapeutics toward SARS using laboratory animals. A number of different types of vaccines, such as inactivated virus vaccine, subunit vaccine, DNA vaccine and vaccine using viral expression vector as well as attenuated live vaccine so far reported indicate that neutralizing antibodies play an important role for protection. However, vaccine applicable to humans with the high efficacy and safety has not yet been reported.</div>
</front>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Taguchi, Fumihiro" sort="Taguchi, Fumihiro" uniqKey="Taguchi F" first="Fumihiro" last="Taguchi">Fumihiro Taguchi</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F63 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002F63 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:18939499
   |texte=   [SARS vaccines].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18939499" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021